[1]李泽东,詹　贞,刘　忆,等.帕金森病患者血清鳞状细胞癌抗原（SCC-Ag）表达的临床意义[J].现代检验医学杂志,2019,34(06):70-72.[doi:10.3969 ／ j.issn.1671-7414.2019.06.017]
　LI Ze-dong,ZHAN Zhen,LIU Yi,et al.Significance of SCC Antigen Expression in Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2019,34(06):70-72.[doi:10.3969 ／ j.issn.1671-7414.2019.06.017]
点击复制

帕金森病患者血清鳞状细胞癌抗原（SCC-Ag）表达的临床意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年06期
页码:
70-72
栏目:
论著
出版日期:
2019-12-30

文章信息/Info

Title:
Significance of SCC Antigen Expression in Parkinson’s Disease
文章编号:
1671-7414（2019）06-070-03
作者:
李泽东; 詹　贞; 刘　忆; 许广敏; 滕　弘
（南京医科大学附属脑科医院，南京　210029）
Author(s):
LI Ze-dong; ZHAN Zhen; LIU Yi; XU Guang-min; TENG Hong
（Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing 210029,China.）
关键词:
帕金森病; 鳞状细胞癌抗原; 生物标志物
分类号:
R744.9；R392.11
DOI:
10.3969 ／ j.issn.1671-7414.2019.06.017
文献标志码:
A
摘要:
目的　观察鳞状细胞癌抗原（SCC-Ag）在帕金森病表达中的意义。方法　采用化学发光微粒子免疫检测法测 定926 例帕金森病患者和776 例门诊保健体检者血清SCC-Ag 水平。结果　帕金森病患者中血清SCC-Ag 异常表达率明 显高于对照组（13.39% vs 2.45%），差异有统计学意义（χ2=65.330，P =0.000）。其中，男性异常表达率高于女性（9.50% vs 3.89%），差异有统计学意义（χ2=9.583，P =0.002）。71~80 岁组异常表达率高于51~60 岁组，61~70 岁组，81~90 岁组， 91~95 岁组（5.51% vs 0.97%，3.31%，3.67%，0.11%），差异有统计学意义（χ2=32.428，P =0.000）。 Hoehn-Yahr 5 期 异常表达率高于H-Y 1 期，H-Y 2 期，H-Y 3 期和H-Y 4 期（46.15% vs 1.30%，3.90%，17.92%，31.36%），差异有统 计学意义（χ2=90.957，P =0.000）。结论　SCC-Ag 对帕金森病辅助诊断、疾病严重程度有重要的临床意义。
Abstract:
Objective　 To investigate the significance of SCC-Ag expression in Parkinson’s disease. Methods　Serum SCCAg levels in 926 patients with Parkinson’s disease（PD） and 776 cases of out-patient physical examination were determined by chemiluminescent microparticle immunoassay. Results　The abnormal expression rate of SCC-Ag in serum of PD group was significantly higher than that of the control group （13.39% vs 2.45%，χ2=65.330, P =0.000）. Among them, the abnormal expression rate in men was higher than that in women,and the difference was statistically significant(9.50% vs 3.89%, χ2=9.583, P =0.002). The abnormal expression rate of the 71~80 age group was higher than that of the 51~60 age group, 61~70 age group , 81~90 age group , and 91~95 age group（5.51% vs 0.97%，3.31%，3.67%，0.11%）, with statistically significant differences （χ2=32.428, P =0.000）. The abnormal expression rate of hoehn-yahr in stage 5 was higher than that in stage 1, stage 2 , stage 3 and stage 4（46.15% vs 1.30%，3.90%，17.92%，31.36%）, with statistically significant differences （χ2=90.957, P =0.000）. Conclusion　SCC-Ag plays an important role in the diagnosis and severity of Parkinson’s disease.

参考文献/References:

[1]　PARNETTI L, CASTRIOTO A, CHIASSERINI D, et al. Cerebrospinal fluid biomarkers in Parkinson disease[J]. Nat Rev Neurol, 2013, 9(3):131-140.
[2]　DE LAU L M, KOUDSTAAL P J, HOFMAN A, et al. Serum uric acid levels and the risk of Parkinson’s disease[J]. Ann Neurol, 2005, 58(5):797-800.
[3]　PELLECCHIA M T, SANTANGELO G, PICILLO M, et al. Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson’s disease patients[J]. J Neurol, 2013, 260(2):438-444.
[4]　QIANG J K, WONG Y C, SIDEROWF A, et al. Plasma apolipoprotein A1 as a biomarker for Parkinson’s disease[J]. Ann Neurol, 2013, 74(1):119-127.
[5]　KHALIL M, TEUNISSEN CE, OTTO M, et al. Neurofilaments as biomarkers in neurological disorders[J]. Nat Rev Neurol，2018,14 (10):577-589.
[6]　KATO H, TORIGOE T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma[J]. Cancer, 1977,40(4):1621-1628.
[7]　MIZUMOTO T, HIYAMA T, QUACH D T, et al. Magnifying endoscopy with narrow band imaging in estimating the invasion depth of superficial esophageal squamous cell carcinoma[J]. Digestion, 2018,98(4):249-256.
[8]　MOLINA R, FILELLA X, AUGE J M, et al. Tumor markers (CEA, CA 125,CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors[J]. Tumour Biol, 2003, 24(4):209-218.
[9]　QUINN P L, OLIVER J B, MAHMOUD O M. Cost-effectiveness of sentinel lymph node biopsy for head and neck cutaneous aquamous cell carcinoma[J]. J Surg Res, 2019 , 241:15-23.
[10] SATO H, KOIDE Y, SHIOTA M, et al. Outcomes of anal squamous cell carcinoma treated with chemoradiotherapy[J]. Gan To Kagaku Ryoho, 2018, 45(13):1907-1909.
[11] ISLAMI F, FEDEWA S A, JEMAL A. Trends in cervical cancer incidence rates by age, race/ethnicity, histological subtype, and stage at diagnosis in the United States[J]. Prev Med, 2019, 123(19):316-323.
[12] RIZZUTO I, MACNAB W, NICHOLSON R, et al. Less radical surgery for women with early stage cervical cancer: Our experience on radical vaginal trachelectomy and laparoscopic pelvic lymphadenectomy[J]. Gynecol Oncol Rep, 2019, 28:65-67.
[13] CLIFFORD GM, TENET V, GEORGES D, et al. Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: Whole viral genome sequences from 7116 HPV16-positive women[J]. Papillomavirus Res, 2019,7:67-74.
[14] INAOKI M, KAJI K, FURUSE S, et al. Pemphigus foliaceus developing after metastasis of cutaneous squamous cell carcinoma to regional lymph nodes[J]. J Am Acad Dermatol, 2001,45(5):767-770.
[15] TRAMONTI G, FERDEGHINI M, DONADIO C, et al. Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 211, TPA, and TPS) in patients without evidence of neoplasia[J]. Cancer Detect Prev, 2000, 24(1):86-90.
[16] TAYLOR K S, COOK J A, COUNSELL C E. Heterogeneity in male to female risk for Parkinson’s disease[J]. J Neurol Neurosurg Psychiatry, 2007, 78(8): 905?906.
[17] PRINGSHEIM T, JETTE N, FROLKIS A, et al. The prevalence of Parkinson’s disease: a systematic review and meta ? analysis[J]. Mov Disord, 2014, 29(13):1583?1590.

相似文献/References:

[1]武 琪a,陈 亮b,张宝华c.帕金森病患者血清和脑脊液褪黑素水平变化及其临床意义[J].现代检验医学杂志,2017,32(05):90.[doi:10.3969/j.issn.1671-7414.2017.05.017]
　WU Qia,CHEN Liangb,ZHANG Bao-huac.Changes and Clinical Significance of Melatonin in Blood and Cerebrospinal Fluid of Patients with Parkinson's Disease[J].Journal of Modern Laboratory Medicine,2017,32(06):90.[doi:10.3969/j.issn.1671-7414.2017.05.017]
[2]武 琪a,张宝华b.Nrf2基因启动子-653G/A,-651G/A和-617C/A位点单核苷酸多态性与帕金森病易感性的关联性研究[J].现代检验医学杂志,2017,32(06):60.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　WU Qia,ZHANG Bao-huab.Association between Nrf2 Gene -653G/A,-651G/A and -617C/A Polymorphism and Susceptibility of Parkinson's Disease[J].Journal of Modern Laboratory Medicine,2017,32(06):60.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[3]尚天明,毕开湘.唾液 α- 突触核蛋白 (SNCA) 与嗅觉评估在帕金森病早期筛查中的应用研究[J].现代检验医学杂志,2020,35(06):95.[doi:doi:10.3969/j.issn.1671-7414.2020.06.023]
　SHANG Tian-ming,BI Kai-xiang.Application Research of Olfactory Assessment and Salivary SNCA in EarlyScreening of Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2020,35(06):95.[doi:doi:10.3969/j.issn.1671-7414.2020.06.023]
[4]李群英,甄时建,何树光,等.帕金森病患者治疗期间血清miR-153，miR-128b水平表达与非运动症状的相关性研究[J].现代检验医学杂志,2021,36(05):120.[doi:10.3969/j.issn.1671-7414.2021.05.027]
　LI Qun-ying,ZHEN Shi-jian,HE Shu-guang,et al.Research on Correlation between Expression of Serum miR-153, miR-128bLevels and Non-motor Symptoms in Patients with Parkinson’s DiseaseDuring Treatment Period[J].Journal of Modern Laboratory Medicine,2021,36(06):120.[doi:10.3969/j.issn.1671-7414.2021.05.027]
[5]闫　欣,商素亮,李　娜,等.血浆S1P和HDL-C表达水平与帕金森病患者临床症状的相关性研究[J].现代检验医学杂志,2022,37(03):182.[doi:10.3969/j.issn.1671-7414.2022.03.038]
　YAN Xin,SHANG Su-liang,LI Na,et al.Correlation between Plasma S1P, HDL-C Expressions Levels and Clinical Symptoms in Patients with Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2022,37(06):182.[doi:10.3969/j.issn.1671-7414.2022.03.038]
[6]白 雪,董巧云,赵 丽,等.帕金森病患者血清miR-7 和α-Syn 表达水平与认知功能障碍的相关性研究[J].现代检验医学杂志,2023,38(04):78.[doi:10.3969/j.issn.1671-7414.2023.04.014]
　BAI Xue,DONG Qiaoyun,ZHAO Li,et al.Correlation between Serum miR-7 and α-Syn Expression Levels and Cognitive Impairment in Patients with Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2023,38(06):78.[doi:10.3969/j.issn.1671-7414.2023.04.014]
[7]郑德泉,江 华,林锦标,等.帕金森病患者血清NPASDP-4，MBP 水平表达与认知功能障碍及严重程度的诊断价值研究[J].现代检验医学杂志,2024,39(03):17.[doi:10.3969/j.issn.1671-7414.2024.03.003]
　ZHENG Dequan,JIANG Hua,LIN Jinbiao,et al.Study on the Diagnostic Value of Serum NPASDP-4 and MBP Level Expression with Cognitive Dysfunction and Severity in Parkinson’s Disease Patients[J].Journal of Modern Laboratory Medicine,2024,39(06):17.[doi:10.3969/j.issn.1671-7414.2024.03.003]
[8]牛荣荣,宋世雄,宋 蕾.帕金森病患者血清FGF22 和CXCL16 水平检测对认知障碍的诊断价值[J].现代检验医学杂志,2024,39(03):152.[doi:10.3969/j.issn.1671-7414.2024.03.026]
　NIU Rongrong,SONG Shixiong,SONG Lei.Diagnostic Value of Serum FGF22 and CXCL16 Levels in Patients with Parkinson’s Disease for Cognitive Impairment[J].Journal of Modern Laboratory Medicine,2024,39(06):152.[doi:10.3969/j.issn.1671-7414.2024.03.026]
[9]曹明月,王 巍,周美宁.LPIN1/PPARA 通过抑制SLC47A1 介导的神经元铁死亡缓解帕金森病模型大鼠病情进展的机制研究[J].现代检验医学杂志,2024,39(04):63.[doi:10.3969/j.issn.1671-7414.2024.04.012]
　CAO Mingyue,WANG Wei,ZHOU Meining.Mechanism Study on LPIN1/PPARA Alleviating the Progression of Parkinson’s Disease in Rats by Inhibiting SLC47A1-Mediated Ferroptosis of Neurons[J].Journal of Modern Laboratory Medicine,2024,39(06):63.[doi:10.3969/j.issn.1671-7414.2024.04.012]

备注/Memo

备注/Memo:
作者简介：李泽东（1982-），男，博士，主治医师，研究方向：神经系统变性和免疫疾病，E-mail：lizedong12@163.com。 通讯作者：滕弘（1970-），女，硕士，主任医师，研究方向：神经系统重症疾病，E-mail：tenghong2009@163.com 收稿日期：2019-03-27
更新日期/Last Update: 2019-12-25